

Cadila Healthcare Limited
Investor Presentation
November 2013



Well integrated pharma player with global footprints

>60 years
Operational experience

$ 1 bn +
Global Revenues

>7% of sales
Spent on R&D annually

20+ mfg. sites
Producing >13 bn pills annually

>20% CAGR
In Sales and Net Profits (FY '08 – FY '13)

1st Indian Company
To discover & develop an NCE in-house : Lipaglyn (Saroglitazar)

15,000+ employees
Across the globe, with 1050+ for R&D

~ 23% CAGR
In Net Worth (FY '08 – FY '13)

7 NCE programmes
In pipeline, at various stages of clinical trials

Among top 5
Pharmaceutical Companies in India

20 brands
Among top 300 brands in India

19 Biosimilars
In pipeline, including 2 novel biologics

10th largest
Generic co. in US in terms of prescriptions

~ $ 2.5 bn
Market Cap

950+ patents
Filed globally

History of achieving milestones consistently



25 fold growth in sales over last 16 years…

2000 Rs. 1000 cr

2006 $400 mn

2010 $1 bn

…with significant external recognition


Annual Sales

Rs. 200 cr. in 1995

Economic Times Emerging Company of the year 2010

Kaizen Institute - Operational Excellence in Tablet Manufacturing in 2010

Key businesses for our journey Beyond the Billion



India formulations

Aspirations

- Maintain strong leadership position in key areas – CVS, GI, respiratory, female healthcare
- Continue to be one of the significant contributors to revenues and profits

Strengths to be leveraged

- One of the largest market players with leading positions in key therapy areas
- Strong brand equity : 20 brands among top 300 in India
- New product launches : 40+ in H1 13-14 (incl. line extensions), with 9 First-in-India
- Recently launched Lipaglyn (Saroglitazar), the first NCE discovered and developed indigenously by an Indian Pharma company
- In-licensing arrangements with global players

Market size*	: **Rs. 720 bn+**
Market growth*	: **7%**
Zydus size**	: **Rs. 32 bn+**
Market Share*	: **4.5%**
Zydus growth**	: **16%**

A first for the nation




*** All market related information sourced from AIOCD AWACS MAT Sep-13**
**** Zydus numbers including Biochem as reported by AIOCD AWACS MAT Sep-13**

US Oral Solids

Market size*	: **>$ 50 bn**
Market growth*	: **15-17%**
Zydus size**	: **~ $ 276 mn**
Zydus growth**	: **6%**

34%+ CAGR in Sales (Last 5 years)



Aspirations

- Be amongst the top 10 generic cos. in US with continued strong focus on customer needs
- One of the significant contributors to revenues and profits

Strengths to be leveraged

- Among top 3 for 2/3rd of the products marketed in US
- Highly efficient service levels, makings us the 'Preferred supplier' for our customers
- Cost competitiveness – through continuous improvement in manufacturing processes
- Robust regulatory pipeline, with increasing focus on complex and niche products.
- 150+ ANDA fillings, 70+ approvals and 50+ product launches till September,2013
- Nesher – two products already in the market.

*** Approx. numbers as per IMS Report**
**** Zydus numbers includes Nesher, as reported in books, for FY 2012-13**

Brazil

Market size* : **>$ 16 bn**
Market growth* : **12-14%**
Zydus size** : **Rs. 2,384 mn**
Zydus growth** : **-4%**



Aspirations

- To be among top 15 companies in 2015

Strengths to be leveraged

- Presence in branded generics and generic generics segments with a continued focus on brand building initiatives
- Local manufacturing site
- Robust product pipeline from India – 100+ filings, 40 approvals
- Focused segments (Branded) – female healthcare, hepatology, CNS, CVS and Nutraceuticals
- Product launches : 20+ branded, 15+ generic generics

*** Approx. numbers as per IMS Report**
**** Zydus numbers as reported in books for FY 2012-13**

Mexico

Market size* : **~ US$ 10 bn**
Market growth* : **8-10%**



Aspirations

- Build a profitable business in 2015
- 40+ product launches and 60 + fillings by 2015

Strengths to be leveraged

- Focused segments (Branded) – CNS, metabolic disorders and respiratory
- Building product pipeline from India – 25+ filings and 6 approvals so far.
- Commenced commercial operations in Q1 FY 14 with the launch of first product in the market from India
- Launched 4 products in the market so far

*** Approx. numbers as per IMS Report**

Other Global Markets

Aspirations : To be amongst the leading players in these generics markets

EU

Mkt. Size* : ~**$ 6.5 bn**
(France + Spain Gx)
Mkt. Gr. : **15-18%**
Zydus Size **:
Rs. 3,697 mn
Zydus Gr. : **24%**

- 9th largest in France, among top 20 in Spain
- Expansion through new products : launched 110+ molecules in France and 80+ molecules in Spain so far (incl. several 'Day 1')
- Leveraging India cost advantage : 160+ new products and 60+ site transfer filings so far, >40% of sales supplied from India

Japan

Mkt. Size* : ~**$ 7 bn**
Mkt. Gr. : **8-10%**
Zydus Size ** :
Rs. 603 mn
Zydus Gr. : **16%**

- 25+ products in market, including 15+ in-licensed
- Only Indian pharma company to develop, file and launch products from India
- To expand market coverage with new launches, customer coverage and co-development initiatives

Emerging Mkts.

Mkt. Size* : >**$ 13 bn**
Mkt. Gr. : **12-13%**
Zydus Size **:
Rs. 3,134 mn
Zydus Gr. : **66%**

- Operations in 8 markets of Asia Pacific and Africa with leadership positions in several of these markets
- Consolidated the Branded Generic business in the key markets of Asia Pacific, Africa and Middle East
- Increased product development activities supported by strong regulatory teams

*** Approx. numbers as per GERS Report for Europe, as per IMS for Japan and as per EvaluatePharma for emerging markets**
**** Zydus numbers as reported in books for FY 2012-13**

Other Businesses

Wellness

Sugar Free EverYuth

Zydus Size **:
Rs. 4,100 mn
Zydus Gr. : **19%**

Nutralite Healthier than Butter ACTI LIFE

Aspirations : To create niches in wellness space through innovation

- Leadership in sugar substitutes (94%+ market share), peel-off and scrub range for skin-care and margarine categories in India
- Re-launched EverYuth brand with contemporary packaging, improved formulations and new marketing programme
- Launched Nutralite with Omega 3 to strengthen its health positioning

Animal Health

Zydus Size **:
Rs. 2,370 mn
(incl. Bremer)
Zydus Gr. : **22%**

Aspirations : To be a comprehensive, global animal healthcare provider

- One of India's leading animal healthcare co.
- Wide range of drugs, feed supplements and vaccines for livestock, companion animals and poultry
- Presence in key markets across Europe, South America, Asia and Africa through Bremer Pharma, Germany

APIs



Zydus Size **:
Rs. 3,099 mn
Zydus Gr. : **9%**

Aspirations : To be a 'reliable' service provider to customers

- Backward integration capabilities to meet captive API requirements
- Operations in India, US and select markets of Europe, Latin America, Asia Pacific and Middle East regions
- Continuous endeavour to improve service levels by improving cost competitiveness and continuous process improvement

** Zydus numbers as reported in books for FY 2012-13

Joint Ventures and Alliances

Aspirations : Value creation through win-win alliances and be a partner of choice

Zydus Takeda JV

- State-of-the-art mfg. facility for APIs of Nycomed
- Commissioned the expanded facility to manufacture complex high-end APIs
- Commenced mfg. and supply of 10 products so far (incl. 4 for validation)

Zydus Hospira JV

- State-of-the-art cytotoxic facility approved by leading authorities like MHRA, USFDA, TGA, Health Canada
- Commercial supplies commenced for : EU (6 products) and US (4 products)
  - Expanded scope of collaboration to cover additional products



Bayer Zydus JV

- Operates in female healthcare, metabolic disorders, diagnostic imaging, CVS, diabetes and oncology segments in India
- Leveraging strengths of Bayer's optimised product portfolio and Zydus' marketing and distribution capabilities
- JV scope covers launch of innovator products of Bayer

Out-licensing deal with Abbott

- Licensed 30+ products for ~18 key emerging markets
- Commenced commercial supply of products under the deal and shipped 4 products so far.

Biosimilars


Aspirations :

Drive substantial business by 2015 through…

- Marketing in India and emerging markets
- Licensing / co-development for advanced markets

Strengths to be leveraged

- Dedicated facility for product development and mfg.
- 170+ experienced scientists
- Strong pipeline: 17 biosimilars and 2 novel products
- Strong IP position either through own patent or non-infringing processes



No	Product	Indication	Cloning	Process Devp.	Pre-Clinical Devp.	Regulatory Permission	Clinical Devp.	Mktg. Authori-sation
1	G-CSF	Oncology	LAUNCHED (in India)					
2	Peg G-CSF	Oncology						
3	IFN α-2b	Infectious diseases						
4	Peg IFN α-2b	Infectious diseases						
5	EPO	Oncology/Nephrology						
6	Teriparatide	Osteoporosis						
7	IFN β 1b	Multiple Sclerosis						
8	Prod 1	Nephrology						
9	Prod 2	Rheumatoid Arthritis						
10	MAB 1	Oncology/RA						
11	MAB 2	Inflammation						
12	MAB 3	Oncology						
13	MAB 4	Oncology						
14	Prod 3	AMI						
15	Prod 4	Fertility						
16	Prod 5	Fertility						
17	Prod 6	Fertility						
18	MAB 5	Rabies						
19	PEG-EPO	Nephrology						

New Technologies

Aspirations : To be a leading market player in complex technologies



Transdermals

- State-of-the-art product development and manufacturing facility set-up in SEZ near Ahmedabad
- 4 patches already filed with US FDA
- Several other patches under development



Vaccines

- Fully approved Vaccine Technology Center in India with 60+ dedicated scientists
- 1st Indian co. to launch H1N1 vaccine
- Several vaccines under different stages of development
- Dedicated manufacturing capabilities built for several vaccines

Injectables, Inhalables, Ointments

- Building product pipeline : ANDAs filed with US FDA for
  - 28 injectables (including 19 for a partner) and 5 nasal products
  - 4 ointments
- 8 approvals for injectables so far (7 for partner and 1 for own), commercial production and supply of 6 of them (incl. own product) have commenced

NCE research

Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020

Key strengths

- State-of-the art research facility
- Capability of target identification to pre-clinical research / early clinical development
- 400+ scientists dedicated for NME research



NCE Pipeline

Project	Target	Indication	Drug Discovery	Lead optimi-saiton	Pre-clinical Develop-ment	IND	Phase I	Phase II	Phase III	NDA
Saro-glitazar	PPAR-α,γ	Dyslipidemia	First glitazar to be approved in the world. Launched in India as "LIPAGLYN"							
ZYH7	PPAR-α	Dyslipidemia								
ZYD1	GLP-1 Agonist	Diabetes, Obesity								
ZYOG1	Oral GLP-1 Agonist	Diabetes, Obesity								
ZYGK1	Glocokinase Activator	Diabetes								
ZYPH 0907	Oral PTH	Osteoporosis								
ZYG19	GPR 119 Agonist	Diabetes								

World class infrastructure to support growth journey

Formulations Mfg.



Oral Solids (India)

- Ahmedabad (USFDA)
- Baddi (USFDA)
- Goa
- Sikkim
- Ahmedabad SEZ (onco. and others)
- Daman (Biochem)

Oral Solids (outside India)

- US (Nesher Pharma – controlled substances)
- Brazil
- Japan
- Germany (animal health)

Other dosage forms (India)

- Transdermals – Ahmedabad SEZ
- Topicals – Ahmedabad
- Vaccines Mfg. - Ahmedabad

API Mfg.



- Ankleshwar (USFDA)
- Dabhasa (USFDA)
- Oncology API, Ahmedabad (USFDA)
- Biologics active substances and MABs, Ahmedabad

Mfg. facilities for partners



- Cytotoxic Injectible for Hospira JV – Ahmedabad SEZ (USFDA)
- API facility for Nycomed JV - Mumbai
- Cytotoxic Injectible for BSV JV – Ahmedabad SEZ


Product Development



- Formulations Development, Ahmedabad (400+ scientists)
- API Process Research, Dabhasa (150+ scientists)
- Vaccine Research, Ahmedabad (60+ scientists)

Pillars of Organisational Health

Key initiatives identified to improve overall organisation health in four key areas.



Creating value and developing talent across the organisation

Enhancing bottom-up innovation across the organisation


Promoting collaboration across businesses and functions

Strengthening accountability by proper performance management

Key Financial Numbers – H1 FY 2013-14

Consolidated (Rs. Mio.)	Amount	Gr.%
Total Income from Operations	33,838	7.7%
EBIDT	5,463	-7.1%
EBIDT % to Income from Ops.	16.1%	
Profit before tax	4,250	1.5%
PBT % to Income from Ops.	12.6%	
Net Profit	3,784	31.0%
Net Profit % to Income from Ops.	11.2%	
Debt net of cash (30-Sep-13)	26,760	
Capex (H1 FY 2013-14)	4,171	

Segment-wise Gross Sales



Steady growth Markets, 34% of total, Up 8% y-o-y

Home Markets, 66% of total, Up 10% y-o-y

Thank You.

Safe Harbour Statement

This presentation may include certain "forward looking statements" , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements . The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Cadila Healthcare Ltd.

www.zyduscadila.com